Details of the Drug

General Information of Drug (ID: DMNFUZR)

Drug Name
Enalapril
Synonyms
Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 376.4
Topological Polar Surface Area (xlogp) -0.1
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
63.5% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The renal clearance of drug is 158 +/- 47 mL/min [6]
Elimination
Enalapril is mainly eliminated through renal excretion, where approximately 94% of the total dose is excreted via urine or feces as either enalaprilat or unchanged parent compound [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 35 - 38 hours [3]
Metabolism
The drug is metabolized via the de-esterification mediated by hepatic esterases [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.77178 micromolar/kg/day [8]
Water Solubility
The ability of drug to dissolve in water is measured as 25 mg/mL [4]
Chemical Identifiers
Formula
C20H28N2O5
IUPAC Name
(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
Canonical SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
InChI
InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
InChIKey
GBXSMTUPTTWBMN-XIRDDKMYSA-N
Cross-matching ID
PubChem CID
5388962
ChEBI ID
CHEBI:4784
CAS Number
75847-73-3
DrugBank ID
DB00584
TTD ID
D00SEB
VARIDT ID
DR00010
INTEDE ID
DR0573
ACDINA ID
D00229

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 2 (SLC15A2) DT8QKNP S15A2_HUMAN Substrate [10]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [11]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [12]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [15]
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Substrate [16]
Dipeptidase (pepV) DEQMBHW Q84BU9_LACLH Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 1.85E-02 5.14E-02 3.36E-01
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTP OATP1A2 2.28E-01 -5.92E-02 -1.22E-01
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 3.85E-03 1.01E-01 7.72E-01
Peptide transporter 2 (SLC15A2) DTP PEPT2 8.33E-02 -3.63E-02 -1.27E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 8.47E-01 1.14E-02 8.20E-02
Carboxylesterase 1 (CES1) DME CES1 1.24E-01 1.06E-01 4.92E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Enalapril
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Enalapril and Aliskiren. Hypertension [BA00-BA04] [92]
Losartan DM72JXH Major Increased risk of hyperkalemia by the combination of Enalapril and Losartan. Hypertension [BA00-BA04] [93]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Enalapril and TAK-491. Hypertension [BA00-BA04] [93]
Indapamide DMGN1PW Moderate Additive hypotensive effects by the combination of Enalapril and Indapamide. Hypertension [BA00-BA04] [94]
Trichlormethiazide DMHAQCO Moderate Additive hypotensive effects by the combination of Enalapril and Trichlormethiazide. Hypertension [BA00-BA04] [94]
Telmisartan DMS3GX2 Major Increased risk of hyperkalemia by the combination of Enalapril and Telmisartan. Hypertension [BA00-BA04] [93]
Irbesartan DMTP1DC Major Increased risk of hyperkalemia by the combination of Enalapril and Irbesartan. Hypertension [BA00-BA04] [93]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Enalapril (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [95]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Enalapril due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [96]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Enalapril and Repaglinide. Acute diabete complication [5A2Y] [97]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Enalapril and Glibenclamide. Acute diabete complication [5A2Y] [97]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Enalapril and Tolazamide. Acute diabete complication [5A2Y] [97]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Enalapril and Insulin-glulisine. Acute diabete complication [5A2Y] [97]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Enalapril and Insulin-aspart. Acute diabete complication [5A2Y] [98]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Enalapril and Glipizide. Acute diabete complication [5A2Y] [97]
Nifedipine DMSVOZT Minor Additive hypotensive effects by the combination of Enalapril and Nifedipine. Angina pectoris [BA40] [99]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [100]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Enalapril and Linezolid. Bacterial infection [1A00-1C4Z] [101]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Enalapril and Cariprazine. Bipolar disorder [6A60] [102]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Enalapril and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [103]
Mannitol DMSCDY9 Moderate Additive hypotensive effects by the combination of Enalapril and Mannitol. Bronchiectasis [CA24] [94]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Enalapril and Olopatadine. Conjunctiva disorder [9A60] [104]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Enalapril and Drospirenone. Contraceptive management [QA21] [105]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Enalapril and Ardeparin. Coronary thrombosis [BA43] [93]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Enalapril and Selegiline. Depression [6A70-6A7Z] [101]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Enalapril and Isocarboxazid. Depression [6A70-6A7Z] [101]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Enalapril and Tranylcypromine. Depression [6A70-6A7Z] [101]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Enalapril and OPC-34712. Depression [6A70-6A7Z] [102]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Enalapril and Phenelzine. Depression [6A70-6A7Z] [101]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Enalapril and Nitroglycerin. Diabetic foot ulcer [BD54] [106]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Enalapril due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [96]
Ethacrynic acid DM60QMR Moderate Additive hypotensive effects by the combination of Enalapril and Ethacrynic acid. Essential hypertension [BA00] [107]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Enalapril and Phenoxybenzamine. Essential hypertension [BA00] [108]
Acetazolamide DM1AF5U Moderate Additive hypotensive effects by the combination of Enalapril and Acetazolamide. Glaucoma [9C61] [94]
Methazolamide DM7J2TA Moderate Additive hypotensive effects by the combination of Enalapril and Methazolamide. Glaucoma [9C61] [94]
Dichlorphenamide DMH7IDQ Moderate Additive hypotensive effects by the combination of Enalapril and Dichlorphenamide. Glaucoma [9C61] [107]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Enalapril and Eplerenone. Heart failure [BD10-BD1Z] [109]
Furosemide DMMQ8ZG Moderate Additive hypotensive effects by the combination of Enalapril and Furosemide. Heart failure [BD10-BD1Z] [94]
Amiloride DMRTSGP Major Increased risk of hyperkalemia by the combination of Enalapril and Amiloride. Heart failure [BD10-BD1Z] [110]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Enalapril and Bumetanide. Heart failure [BD10-BD1Z] [94]
Hydroflumethiazide DMVPUQI Moderate Additive hypotensive effects by the combination of Enalapril and Hydroflumethiazide. Heart failure [BD10-BD1Z] [94]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Brentuximab vedotin. Hodgkin lymphoma [2B30] [111]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [112]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Enalapril and Isosorbide mononitrate. Hydrocephalus [8D64] [106]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Enalapril and Mipomersen. Hyper-lipoproteinaemia [5C80] [113]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Enalapril and BMS-201038. Hyper-lipoproteinaemia [5C80] [114]
Potassium chloride DMMTAJC Major Increased risk of hyperkalemia by the combination of Enalapril and Potassium chloride. Hypo-kalaemia [5C77] [115]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Enalapril and Propiomazine. Insomnia [7A00-7A0Z] [102]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Enalapril and ITI-007. Insomnia [7A00-7A0Z] [102]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Enalapril and Porfimer Sodium. Lung cancer [2C25] [116]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [117]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Idelalisib. Mature B-cell leukaemia [2A82] [118]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Clofarabine. Mature B-cell lymphoma [2A85] [119]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Enalapril due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [120]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Enalapril and Promethazine. Nausea/vomiting [MD90] [102]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Enalapril and Polythiazide. Oedema [MG29] [94]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Enalapril and Safinamide. Parkinsonism [8A00] [101]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Enalapril and Rasagiline. Parkinsonism [8A00] [101]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Enalapril and Terazosin. Prostate hyperplasia [GA90] [108]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Enalapril and Silodosin. Prostate hyperplasia [GA90] [108]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Enalapril and Levomepromazine. Psychotic disorder [6A20-6A25] [102]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Enalapril and Fluphenazine. Psychotic disorder [6A20-6A25] [102]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Enalapril and Leflunomide. Rheumatoid arthritis [FA20] [120]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Enalapril and Quetiapine. Schizophrenia [6A20] [102]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Enalapril and Mesoridazine. Schizophrenia [6A20] [102]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Enalapril and Thioridazine. Schizophrenia [6A20] [102]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Enalapril and Aripiprazole. Schizophrenia [6A20] [102]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Enalapril and Iloperidone. Schizophrenia [6A20] [102]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Enalapril and Paliperidone. Schizophrenia [6A20] [102]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Enalapril and Molindone. Schizophrenia [6A20] [102]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Enalapril and Thiothixene. Schizophrenia [6A20] [102]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Enalapril and Trifluoperazine. Schizophrenia [6A20] [102]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Enalapril and Risperidone. Schizophrenia [6A20] [102]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Enalapril and Amisulpride. Schizophrenia [6A20] [102]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Enalapril and Asenapine. Schizophrenia [6A20] [102]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Enalapril and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [121]
Tacrolimus DMZ7XNQ Moderate Increased risk of hyperkalemia by the combination of Enalapril and Tacrolimus. Transplant rejection [NE84] [122]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Enalapril and Tolbutamide. Type 2 diabetes mellitus [5A11] [97]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Enalapril and Chlorpropamide. Type 2 diabetes mellitus [5A11] [97]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Enalapril and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [97]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Enalapril and Insulin degludec. Type-1/2 diabete [5A10-5A11] [97]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Enalapril and Methdilazine. Vasomotor/allergic rhinitis [CA08] [102]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Enalapril and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [123]
⏷ Show the Full List of 76 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Maleic acid E00418 444266 Acidulant; Buffering agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearate E00453 2724691 Emulsifying agent; Gelling agent; Glidant; Modified-release agent; Stiffening agent; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Ferrous oxide E00241 14945 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium bicarbonate E00425 516893 Alkalizing agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Zinc stearate E00209 11178 lubricant
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Enalapril 10 mg tablet 10 mg Oral Tablet Oral
Enalapril 20 mg tablet 20 mg Oral Tablet Oral
Enalapril 2.5 mg tablet 2.5 mg Oral Tablet Oral
Enalapril 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6322).
2 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
3 Enalapril: a review of human pharmacology. Drugs. 1985;30 Suppl 1:13-24. doi: 10.2165/00003495-198500301-00004.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Schelling JL: Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357-62. doi: 10.1111/j.1365-2125.1982.tb01991.x.
7 Todd PA, Goa KL: Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs. 1992 Mar;43(3):346-81. doi: 10.2165/00003495-199243030-00005.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
10 Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
11 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
12 Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
13 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
14 The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6.
15 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16 Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397.
17 Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
18 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27 Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
28 Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos. 2013 Nov;41(11):1888-95.
29 Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8.
30 Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76.
31 Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
32 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
33 Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73.
34 Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
35 Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
36 Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
37 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
38 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
39 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
40 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
41 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
42 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
43 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
44 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
45 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
46 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
47 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
48 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
49 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
50 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
51 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
52 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
53 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
54 FDA Drug Development and Drug Interactions
55 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
56 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
57 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
58 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
59 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
60 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
61 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
62 The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
63 Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
64 Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
65 PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
66 Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
67 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
68 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
69 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
70 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
71 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
72 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
73 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
74 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
75 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
76 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
77 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
78 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
79 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
80 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
81 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
82 Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
83 Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
84 Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
85 Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
86 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
87 Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
88 Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
89 Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
90 Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
91 Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
92 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
93 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
94 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
95 Cerner Multum, Inc. "Australian Product Information.".
96 Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
97 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
98 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
99 DeQuattro V "Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide." Clin Cardiol 14 (1991): iv28-32. [PMID: 1893639]
100 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
101 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
102 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
103 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
104 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
105 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
106 Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
107 Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
108 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
109 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
110 Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
111 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
112 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
113 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
114 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
115 Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
116 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
117 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
118 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
119 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
120 Canadian Pharmacists Association.
121 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
122 Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
123 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.